Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by 18F-FDG PET/CT

doi:10.3877/cma.j.issn.1674-0793.2015.03.004

Abstract

Abstract:

Objective

To observe the effect of cetuximab in tumor with small animal PET/CT by establishing the xenogenous implant model of colorectal cancer in nude mice.

Methods

HCT116 and LIM1215 tumor-bearing nude mouse models were developed by subcutaneous implantation of HCT116 and LIM1215 cells into BALB/c-nu mice. The tumor models were divided into the control group and cetuximab treatment group (n=5), and to observe the growth of tumor. Then the tumor models were evaluated by small animal ¹⁸F-FDG PET/CT after one week, and we measured the maximum percentage injected dose per gram from tissue and organ at the same time.

Results

The uptake of ¹⁸F-FDG in tumor tissues was significantly higher than that in normal tissues. Compared with control group, the ¹⁸F-FDG uptake rates of tumors/tissue or organ were generally lower in treatment group, which had significant difference in the ratio of tumor/neck, tumor/tumor and heart/liver (P=0.047、0.008、0.024). But the growth trends of tumor volume had no significant difference between treatment group and control group.

Conclusion

Small animal ¹⁸F-FDG PET/CT can monitor the change of glucose metabolism in tumor, while there is no obvious inhibitory effect in tumor growth with cetuximab treating xenogenous implant nude mice of colorectal cancer.

Key words: ¹⁸F-FDG, PET/CT, Cetuximab, Colorectal cancer, Nude mice, Small animal

Wenwen Li, Guangyin Zhao, Zhao Zhang, Chenglu Long, Ying Huang, Qiao Su. Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by ¹⁸F-FDG PET/CT[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(03): 188-192.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2015.03.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2015/V09/I03/188

Figures/Tables 4

References 14

[1]	汪建平.重视结直肠癌流行病学研究[J].中国实用外科杂志, 2013, 33(8): 622-624.
[2]	Bellomi M, Rizzo S, Travaini LL, et al. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer[J]. Radiol Med, 2007, 112(5): 681-690.
[3]	Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer[J]. World J Gastroenterol, 2014, 20(15): 4208-4219.
[4]	Spindler KL, Christensen IJ, Nielsen HJ, et al. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer [J]. Tumor Biol, 2015 Jan 23. [Epub ahead of print]
[5]	Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer[J]. Drugs, 2004, 64 (1): 109-118.
[6]	VanDijk LK, Boerman OC, Franssen GM, et al. Cetuximab-F(ab′)2-SPECT and FDG-PET for prediction and response monitoring of combined modality treatment of human head and neck carcinomas in a mouse model[J]. J Nucl Med, 2014 Dec 31. [Epub ahead of print]
[7]	Aliaga A, Rousseau JA, Cadorette J, et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18] fluoro-D-glucose in murine models of breast cancer[J]. Mol Imaging Biol, 2007, 9(3): 144-150.
[8]	Monazzam A, Josephsson R, Blomqvist C, et al. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer[J]. Breast Cancer Res, 2007, 9(4): 45.
[9]	Liu FY, Yen TC, Wang JY, et al. Early prediction by ¹⁸F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy[J]. Clin Nucl Med, 2015, 40(3): 200-205.
[10]	Grybauskas M, Daisne JF, Aleknavičius E, et al. Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx[J]. Medicina (Kaunas), 2014, 50(4): 245-248.
[11]	Zerizer I, Al-Nahhas A, Towey D, et al. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9): 1391-1399.
[12]	Koolen BB, Pengel KE, Wesseling J, et al. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 32-40.
[13]	Chung HW, Lee EJ, Cho YH, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(12): 1929-1935.
[14]	Tsuji AB, Sogawa C, Sugyo A, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts[J]. Nucl Med Biol, 2009, 36(4): 379-388.

组别	肿瘤／棕色脂肪	肿瘤／颈肌	肿瘤／心脏	肿瘤／脑	肿瘤／肾脏	肿瘤／肝脏	肿瘤／哈氏腺
A组	0.97±0.18	0.67±0.18	1.14±0.28	0.69±0.11	2.01±0.37	1.22±0.31	1.27±0.10
B组	0.42±0.25	0.41±0.07 ^a，b	0.23±0.07 ^b	0.36±0.19	1.01±0.51	1.05±0.68	0.54±0.30
C组	1.67±0.62	1.51±0.43	2.33±0.65	0.83±0.23	1.70±0.45	1.50±0.52	1.41±0.41
D组	0.75±0.35	0.86±0.35	1.31±0.58	0.75±0.20	1.49±0.40	1.34±0.32 ^c	1.03±0.42

组别	肿瘤／棕色脂肪	肿瘤／颈肌	肿瘤／心脏	肿瘤／脑	肿瘤／肾脏	肿瘤／肝脏	肿瘤／哈氏腺
A组	0.97±0.18	0.67±0.18	1.14±0.28	0.69±0.11	2.01±0.37	1.22±0.31	1.27±0.10
B组	0.42±0.25	0.41±0.07 ^a，b	0.23±0.07 ^b	0.36±0.19	1.01±0.51	1.05±0.68	0.54±0.30
C组	1.67±0.62	1.51±0.43	2.33±0.65	0.83±0.23	1.70±0.45	1.50±0.52	1.41±0.41
D组	0.75±0.35	0.86±0.35	1.31±0.58	0.75±0.20	1.49±0.40	1.34±0.32 ^c	1.03±0.42

[1]	Li Dai, Huiwei Deng, Huajing Guo, Furong Huang. Effect of continuous infusion of esketamine on postoperative sleep quality of patients undergoing laparoscopic colorectal cancer surgery [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 408-412.
[2]	Fu Youhuan Liu, Xiuqin Wu, Cuiting Deng, Qing Su. Model based analysis of response and resistance factors to cetuximab treatment in gastric cancer cell lines [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 385-388.
[3]	Guobing Peng, Jianping Fei. Influence of permanent colostomy on colostomy patient's status and its influencing factors [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(03): 264-268.
[4]	Runzhi Chen, Dongmei Yang, Huiting Xu. PD-1 combined with surufatinib for the treatment of metastatic colon cancer with microsatellite stability and BRAF V600E mutation: A case report and review [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 431-435.
[5]	Yimin E, Sizheng Sun, Xiaoyu Fan, Chunzhao Yu. Present status and prospect of fecal screening for colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(04): 331-336.
[6]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[7]	Xiaona Wang, Wei Tan, Yue Li, Wenyan Jiang. Effects of predictive care on perioperative quality of life, mood, and complication in patients undergoing radical colorectal cancer surgery [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 525-529.
[8]	Daijiang Liu, Junyan Jiang, Xiaoqiang Wan, Shaying Ma. Analysis of survival status and prognostic factors in patients with colorectal cancer with liver metastasis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 284-288.
[9]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[10]	Feifei Wang, Guanglin Wang, Zesong Meng, Baokun Li, Longfei Cao, Juan Zhang, Chaoxi Zhou, Yuanyi Ding, Guiying Wang. Effect of IMPDH1 knockdown on biological behavior of human colon cancer SW480 and HT29 cells [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 884-890.
[11]	Fanbiao Kong, Jianrong Yang. Progress in understanding of relationship between underlying liver diseases and liver metastasis of colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 818-822.
[12]	Yadan Wang, Jing Wu, Boyang Huang, Miaomiao Wang, Chunmei Guo, Hui Su, Canghai Wang, Jing Wang, Pengpeng Ding, Hong Liu. Design and validation of white-light endoscopy model for predicting the nature of colorectal tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 655-661.
[13]	Yanzhao Wang, Pengfei Niu, Changmin Ding, Qingkun Gao, Zhaoya Gao, Ke An, Zhichao Zhai, Qingmin Zeng, Wensheng Zeng, Fuming Lei, Jin Gu. Primary repair of large abdominal wall defect caused by colorectal cancer: our experience with 13 cases [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 557-561.
[14]	Pengtao Ren, Yinghao Hao, Hongxun Ruan, Xiaoning Qin, Yuan Zhang, Meng Li. Lnczc3h7a inhibits proliferation and migration of intestinal cancer cells by targeting CTHRC6 [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 320-325.
[15]	Wenjun Deng, Changzheng Li. Progress on the use of intestinal cleaning agents before colonoscopy [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(03): 192-194.

Please choose a citation manager

Content to export

Observation of cetuximab treatment effect in colorectal cancer xenografted nude mice by ¹⁸F-FDG PET/CT

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 14

Related Articles 15

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export